The diadenosine homodinucleotide P18 improves in vitro myelination in experimental charcot-marie-tooth type 1A

Journal of Cellular Biochemistry

Volumn 115, Issue 1, 2014, Pages 161-167

  Nobbio, Lucilla ^a   Visigalli, Davide ^a   Mannino, Elena ^a   Fiorese, Fulvia ^a   Kassack, Matthias U ^b   Sturla, Laura ^a   Prada, Valeria ^a   De Flora, Antonio ^a   Zocchi, Elena ^a   Bruzzone, Santina ^a   Schenone, Angelo ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

cAMP; CMT1A; DRG CULTURES; MYELINATION; P2X7

Indexed keywords

CALCIUM ION; CYCLIC AMP; MYELIN PROTEIN; PURINERGIC P2X7 RECEPTOR; PURINERGIC P2Y11 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CELL DIFFERENTIATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; HEREDITARY MOTOR SENSORY NEUROPATHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MYELINATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; SCHWANN CELL; SPINAL GANGLION; WESTERN BLOTTING; WILD TYPE;

CAMP; CMT1A; DRG CULTURES; MYELINATION; P2X7;

ANIMALS; CELLS, CULTURED; CHARCOT-MARIE-TOOTH DISEASE; CYCLIC AMP; DINUCLEOSIDE PHOSPHATES; DISEASE MODELS, ANIMAL; EMBRYO CULTURE TECHNIQUES; GANGLIA, SPINAL; MYELIN PROTEINS; RATS; RATS, TRANSGENIC; SCHWANN CELLS;

EID: 84887956948     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24644     Document Type: Article

References (49)

1. Alkayed F, Kashimata M, Koyama N, Hayashi T, Tamura Y, Azuma Y,. 2012. P2Y11 purinoceptor mediates the ATP-enhanced chemotactic response of rat neutrophils. J Pharmacol Sci 120: 288-295.
2. Andõ RD, Méhész B, Gyires K, Illes P, Sperlágh B,. 2010. A comparative analysis of the activity of ligands acting at P2X and P2Y receptor subtypes in models of neuropathic, acute and inflammatory pain. Br J Pharmacol 159: 1106-1117.
3. Basile G, Taglialatela-Scafati O, Damonte G, Armirotti A, Bruzzone S, Guida L, Franco L, Usai C, Fattorusso E, De Flora A, Zocchi E,. 2005. ADP-ribosyl cyclases generate two unusual adenine homodinucleotides with cytotoxic activity on mammalian cells. Proc Natl Acad Sci USA 102: 14509-14514.
4. Bradford MM,. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
5. Brandenburg LO, Jansen S, Wruck CJ, Lucius R, Pufe T,. 2010. Antimicrobial peptide rCRAMP induced glial cell activation through P2Y receptor signalling pathways. Mol Immunol 47: 1905-1913.
6. Brockes JP, Fields KL, Raff MC,. 1979. Studies on cultured rat Schwann cells. I. Establishment of purified populations from cultures of peripheral nerve. Brain Res 165: 105-118.
7. Bruzzone S, Dodoni G, Kaludercic N, Basile G, Millo E, De Flora A, Di Lisa F, Zocchi E,. 2007. Mitochondrial dysfunction induced by a cytotoxic adenine dinucleotide produced by ADP-ribosyl cyclases from cADPR. J Biol Chem 282: 5045-5052.
8. Bruzzone S, Basile G, Chothi MP, Nobbio L, Usai C, Jacchetti E, Schenone A, Guse AH, Di Virgilio F, De Flora A, Zocchi E,. 2010. Diadenosine homodinucleotide products of ADP-ribosyl cyclases behave as modulators of the purinergic receptor P2X7. J Biol Chem 285: 21165-21174.
9. Di Virgilio F,. 1995. The P2Z purinoceptor: An intriguing role in immunity, inflammation and cell death. Immunol Today 16: 524-528.
10. d'Ydewalle C, Benoy V, Van Den Bosch L,. 2012. Charcot-Marie-Tooth disease: Emerging mechanisms and therapies. Int J Biochem Cell Biol 44: 1299-1304.
11. Fledrich R, Stassart RM, Sereda MW,. 2012. Murine therapeutic models for Charcot-Marie-Tooth (CMT) disease. Br Med Bull 102: 89-113.
12. Fulgenzi A, Ticozzi P, Gabel CA, Dell'Antonio G, Quattrini A, Franzone JS, Ferrero ME,. 2008. Periodate oxidized ATP (oATP) reduces hyperalgesia in mice: Involvement of P2X7 receptors and implications for therapy. Int J Immunopathol Pharmacol 21: 61-71.
13. Guo L, Moon C, Niehaus K, Zheng Y, Ratner N,. 2012. Rac1 controls Schwann cell myelination through cAMP and NF2/merlin. J Neurosci 32: 17251-17261.
14. Guse AH,. 2005. Second messenger function and the structure-activity relationship of cyclic adenosine diphosphoribose (cADPR). FEBS J 272: 4590-4597.
15. Jang SW, Lopez-Anido C, MacArthur R, Svaren J, Inglese J,. 2012. Identification of drug modulators targeting gene-dosage disease CMT1A. ACS Chem Biol 7: 1205-1213.
16. Jessen KR, Mirsky R, Morgan L,. 1991. Role of cyclic AMP and proliferation controls in Schwann cell differentiation. Ann NY Acad Sci 633: 78-89.
17. Jessen KR, Mirsky R,. 2008. Negative regulation of myelination: relevance for development, injury, and demyelinating disease. Glia 56: 1552-1565.
18. Kaya F, Belin S, Bourgeois P, Micaleff J, Blin O, Fontés M,. 2007. Ascorbic acid inhibits PMP22 expression by reducing cAMP levels. Neuromuscul Disord 17: 248-253.
19. + and its metabolites in cell signaling. Sci Signal 2: mr1.
20. Lee HC,. 2001. Physiological functions of cyclic ADP-ribose and NAADP as calcium messengers. Annu Rev Pharmacol Toxicol 41: 317-345.
21. Li J, Parker B, Martyn C, Natarajan C, Guo J,. 2013. The PMP22 gene and its related diseases. Mol Neurobiol 47: 673-698.
22. Magnone M, Basile G, Bruzzese D, Guida L, Signorello MG, Chothi MP, Bruzzone S, Millo E, Qi AD, Nicholas RA, Kassack MU, Leoncini G, Zocchi E,. 2008. Adenylic dinucleotides produced by CD38 are negative endogenous modulators of platelet aggregation. J Biol Chem 283: 24460-24468.
23. Matsunami N, Smith B, Ballard L, Lensch MW, Robertson M, Albertsen H, Hanemann CO, Müller HW, Bird TD, White R, Chance PF,. 1992. Peripheral myelin protein-22 gene maps in the duplication in chromosome 17p11.2 associated with Charcot-Marie-Tooth 1A. Nat Genet 1: 176-179.
24. Melli G, Höke A,. 2009. Dorsal root ganglia sensory neuronal cultures: A tool for drug discovery for peripheral neuropathies. Expert Opin Drug Discov 4: 1035-1045.
25. Meyer zu Horste G, Prukop T, Liebetanz D, Mobius W, Nave KA, Sereda MW,. 2007. Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy. Ann Neurol 61: 61-72.
26. Millo E, Zocchi E, Galatini A, Benatti U, Damonte G,. 2008. Simple synthesis of P1P2-diadenosine 5'-pyrophosphate. Synthetic Commun 38: 3260-3269.
27. Mithen FA, Cochran M, Cornbrooks CJ, Bunge RP,. 1982. Expression of the trembler mouse mutation in organotypic cultures of dorsal root ganglia. Brain Res 256: 407-415.
28. Monje PV, Soto J, Bacallao K, Wood PM,. 2010. Schwann cell dedifferentiation is independent of mitogenic signaling and uncoupled to proliferation: Role of cAMP and JNK in the maintenance of the differentiated state. J Biol Chem 285: 31024-31036.
29. Monk KR, Naylor SG, Glenn TD, Mercurio S, Perlin JR, Dominguez C, Moens CB, Talbot WS,. 2009. A G protein-coupled receptor is essential for Schwann cells to initiate myelination. Science 325: 1402-1405.
30. Moreschi I, Bruzzone S, Nicholas RA, Fruscione F, Sturla L, Benvenuto F, Usai C, Meis S, Kassack MU, Zocchi E, De Flora A,. 2006. Extracellular NAD+ is an agonist of the human P2Y11 purinergic receptor in human granulocytes. J Biol Chem 281: 31419-31429.
31. Nobbio L, Mancardi G, Grandis M, Levi G, Suter U, Nave KA, Windebank AJ, Abbruzzese M, Schenone A,. 2001. PMP22 transgenic dorsal root ganglia cultures show myelin abnormalities similar to those of human CMT1A. Ann Neurol 50: 47-55.
32. Nobbio L, Vigo T, Abbruzzese M, Levi G, Brancolini C, Mantero S, Grandis M, Benedetti L, Mancardi G, Schenone A,. 2004. Impairment of PMP22 transgenic Schwann cells differentiation in culture: Implications for Charcot-Marie-Tooth type 1A disease. Neurobiol Dis 16: 263-273.
33. Nobbio L, Gherardi G, Vigo T, Passalacqua M, Melloni E, Abbruzzese M, Mancardi G, Nave KA, Schenone A,. 2006. Axonal damage and demyelination in long-term dorsal root ganglia cultures from a rat model of Charcot-Marie-Tooth type 1A disease. Eur J Neurosci 23: 1445-1452.
34. Nobbio L, Sturla L, Fiorese F, Usai C, Basile G, Moreschi I, Benvenuto F, Zocchi E, De Flora A, Schenone A, Bruzzone S,. 2009. P2X7-mediated increased intracellular calcium causes functional derangement in Schwann cells from rats with CMT1A neuropathy. J Biol Chem 284: 23146-23158.
35. Pareyson D, Reilly MM, Schenone A, Fabrizi GM, Cavallaro T, Santoro L, Vita G, Quattrone A, Padua L, Gemignani F, Visioli F, Laurà M, Radice D, Calabrese D, Hughes RA, Solari A, CMT-TRIAAL, CMT-TRAUK groups. 2011. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): A double-blind randomised trial. Lancet Neurol 10: 320-328.
36. Passage E, Norreel JC, Noack-Fraissignes P, Sanguedolce V, Pizant J, Thirion X, Robaglia-Schlupp A, Pellissier JF, Fontés M,. 2004. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 10: 396-401.
37. Pereira JA, Lebrun-Julien F, Suter U,. 2012. Molecular mechanisms regulating myelination in the peripheral nervous system. Trends Neurosci 35: 123-134.
38. Perez-Medrano A, Donnelly-Roberts DL, Honore P, Hsieh GC, Namovic MT, Peddi S, Shuai Q, Wang Y, Faltynek CR, Jarvis MF, Carroll WA,. 2009. Discovery and biological evaluation of novel cyanoguanidine P2X(7) antagonists with analgesic activity in a rat model of neuropathic pain. J Med Chem 52: 3366-3376.
39. Perraud AL, Fleig A, Dunn CA, Bagley LA, Launay P, Schmitz C, Stokes AJ, Zhu Q, Bessman MJ, Penner R, Kinet JP, Scharenberg AM,. 2001. ADP-ribose gating of the calcium-permeable LTRPC2 channel revealed by Nudix motif homology. Nature 411: 595-599.
40. Qi AD, Kennedy C, Harden TK, Nicholas RA,. 2001. Differential coupling of the human P2Y(11) receptor to phospholipase C and adenylyl cyclase. Br J Pharmacol 132: 318-326.
41. Sabéran-Djoneidi D, Sanguedolce V, Assouline Z, Lévy N, Passage E, Fontés M,. 2000. Molecular dissection of the Schwann cell specific promoter of the PMP22 gene. Gene 248: 223-231.
42. Sano Y, Inamura K, Miyake A, Mochizuki S, Yokoi H, Matsushime H, Furuichi K,. 2001. Immunocyte Ca2+ influx system mediated by LTRPC2. Science 293: 1327-1330.
43. Schenone A, Nobbio L, Monti Bragadin M, Ursino G, Grandis M, 2011. Inherited neurophaties. Curr Treat Options Neurol 13: 160-179.
44. Sereda M, Griffiths I, Pühlhofer A, Stewart H, Rossner MJ, Zimmerman F, Magyar JP, Schneider A, Hund E, Meinck HM, Suter U, Nave KA,. 1996. A transgenic rat model of Charcot-Marie-Tooth disease. Neuron 16: 1049-1060.
45. Sereda MW, Meyer zu Hörste G, Suter U, Uzma N, Nave KA,. 2003. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med 9: 1533-1537.
46. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L,. 1998. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338: 278-285.
47. Ullmann H, Meis S, Hongwiset D, Marzian C, Wiese M, Nickel P, Communi D, Boeynaems JM, Wolf C, Hausmann R, Schmalzing G, Kassack MU,. 2005. Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency. J Med Chem 48: 7040-7048.
48. von Kügelgen I,. 2006. Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. Pharmacol Ther 110: 415-432.
49. Yu J, Sheung N, Soliman EM, Spirli C, Dranoff JA,. 2009. Transcriptional regulation of IL-6 in bile duct epithelia by extracellular ATP. Am J Physiol Gastrointest Liver Physiol 296: G563-571.